0001209191-21-070259.txt : 20211217 0001209191-21-070259.hdr.sgml : 20211217 20211217161526 ACCESSION NUMBER: 0001209191-21-070259 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211215 FILED AS OF DATE: 20211217 DATE AS OF CHANGE: 20211217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Chirag K. CENTRAL INDEX KEY: 0001738701 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 211501738 MAIL ADDRESS: STREET 1: C/O AMNEAL PHARMACEUTICALS LLC STREET 2: 400 CROSSING BOULEVARD CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-15 0 0001723128 Amneal Pharmaceuticals, Inc. AMRX 0001738701 Patel Chirag K. C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 1 1 1 0 President & Co-CEO Class A Common Stock 2021-12-15 4 P 0 100000 4.13 A 462566 D Class A Common Stock 2021-12-16 4 P 0 50000 4.25 A 512566 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.06 to $4.18. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.30. The reporting person undertakes to provide the Company, any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. /s/ Meredith Cook, Attorney-in-Fact 2021-12-17